ArticleJournal of assisted reproduction and genetics2026
Assisted oocyte activation re-envisioned: a more physiological approach.
Article in Journal of assisted reproduction and genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine the gamete-specific etiology of severe or total fertilization failure after intracytoplasmic sperm injection (ICSI) and to evaluate the efficacy of individualized assisted oocyte activation (AOA) strategies guided by sperm phospholipase C-zeta (PLCζ) content.
methodsA pilot topographic analysis on PLCζ content in ejaculated, epididymal, and testicular spermatozoa was performed to better understand the fertilization capability of spermatozoa at different maturational stages. The prospective case series included 135 couples with complete or severe fertilization failure following ICSI, who were screened for PLCζ content and allocated as having oocyte- or sperm-related deficiency based on PLCζ assay results. According to gamete-specific deficits, cycles were treated with AOA, that is, ionophore-only, rhPLCζ-only, or combined treatment. Embryological and clinical outcomes of AOA cycles were compared with those of historical non-AOA ICSI cycles.
resultsPLCζ content varied according to the maturity and origin of spermatozoa in the pilot study. Compared with historical cycles, AOA using ionophore and rhPLCζ each rescued fertilization and improved pregnancy outcomes with comparable efficiency. Notably, dual AOA (ionophore + rhPLCζ) yielded the greatest improvements in fertilization (24.1% vs. 73.2%, P < 0.0001), implantation (6.5% vs. 31.7%, P < 0.01), and ongoing pregnancy rates (0% vs. 63.3%, P < 0.0001), even in cycles using testicular spermatozoa.
conclusionsThe introduction of recombinant PLCζ enabled specific correction of gamete-specific fertilization failure. Dual AOA (ionophore + rhPLCζ) was particularly effective in cases of compounded etiology and with immature spermatozoa, supporting a shift from empiric to individualized AOA strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.